Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (918)	1/19/1999 8:22:00 AM
From: John F Beule	Read Replies (1) \| Respond to of 2539

Some good news, for a change: Monsanto and Dow AgroSciences Announce Agreement on Glyphosate And Roundup Ready Crops ST.LOUIS and INDIANAPOLIS, Jan. 19 /PRNewswire/ -- Dow AgroSciences LLC and Monsanto Company (NYSE: MTC) today announced a global, multi-year, toll manufacturing agreement that also licenses Dow AgroSciences the rights to Monsanto's glyphosate herbicide registration data. The agreement will allow Dow AgroSciences to register its own brand of glyphosate herbicide for sale globally. However, Dow AgroSciences will not be able to reference Monsanto data when registering its products for use in Japan. Additionally, the agreement allows Dow AgroSciences to use its own brand of glyphosate herbicide over the top of Roundup Ready soybeans and cotton in the year 2000 in the United States, and beginning in 2001, over the top of Roundup Ready corn in the United States. The agreement does not include lawn and garden uses. Monsanto's Roundup and Roundup Ultra herbicides, which include the active ingredient glyphosate, and Dow AgroSciences glyphosate brand(s) will compete with each other in the agricultural marketplace. As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. The company's 30,000 employees worldwide make and market high-value agricultural products, pharmaceuticals and food ingredients. Dow AgroSciences LLC, based in Indianapolis, Ind., is a global leader in providing pest management and biotechnology products that improve the quality and quantity of the earth's food supply and contribute to the safety, health and quality of life of the world's growing population. The company employs more than 3,000 people in over 50 countries and has worldwide sales of more than $2 billion. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company. This press release contains certain forward-looking statements, including those related to the market for and sales of Roundup Ultra herbicide. These forward-looking statements are based on past experience and current expectations, but actual results may differ materially from those anticipated and there can be no guarantee that future results will be similar to those of the past. Certain factors which could cause actual results to differ materially from expected and historical results include: weather; price; new use; patent expiration; local farming practices; local economic conditions; the type of crops planted; and the availability, price and desirability of competitive products; as well as economic, competitive, governmental, intellectual property, technological and other factors identified in Monsanto Company's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission. SOURCE Monsanto Company CO: Monsanto Company; Dow AgroSciences LLC ST: Missouri IN: CHM AGR SU: 01/19/99 08:01 EST prnewswire.com

To: Anthony Wong who wrote (918)	1/19/1999 10:58:00 AM
From: TheSlowLane	Read Replies (3) \| Respond to of 2539

Seems like 39 is the floor for now. 6.3 mill. shares traded and holding 39. Not too surprising (to me, anyway)...

To: Anthony Wong who wrote (918)	1/19/1999 11:59:00 AM
From: jopawa	Respond to of 2539

DEKALB GENETICS/MONSANTO ACQUIRES WORLDWIDE LICENSE FOR UNIVERSI y of Connecticut's Interferon Technology MADISON, Conn., Jan. 18 /PRNewswire/ -- Stewart Rosenberg, President of BIO-INVESTIGATIONS LTD., has announced that agreements have been signed by The University of Connecticut, DEKALB Genetics Corporation and BIO-INVESTIGATIONS LTD. DEKALB Genetics Corporation, DeKalb, Ill., a member of the Monsanto Global Seed Group, has received an exclusive worldwide license to develop and market corn that may combat virus infection within poultry. The license allows DEKALB, and now the Monsanto Global Seed Group, access to chicken interferon technology that is exclusively licensed by BIO-INVESTIGATIONS LTD and was developed by the University of Connecticut. Corn with sufficient levels of interferon may serve as an alternative or adjunct to vaccines as a means of combating virus infection within poultry. Interferons (IFN) represent a family of cytokines with a wide range of biological effects, including their action as antiviral agents and as modulators of the immune system. In contrast to antibodies elicited by vaccines, IFN may protect cells from the lethal action of a broad spectrum of viruses even after those viruses have entered a cell. The University of Connecticut (UCONN) has developed a technology based on chicken interferon. The lead scientists on this project at UCONN are Dr. Margaret Sekellick and Dr. Philip Marcus of the Department of Molecular and Cell Biology. "Drs. Philip Marcus and Margaret Sekellick have proven themselves to be outstanding researchers in the interferon field," indicated Rosenberg. "When one combines their scientific expertise and capabilities as the technology's inventors, with the proprietary position held by the University on the discovery, and then adds the worldwide leadership position in agricultural biotechnology of DEKALB and the Monsanto Global Seed Group, we are optimistic that there will be some significant advances in the poultry industry as a result of this technology." The University of Connecticut is a public institution of higher education and is Connecticut's only public research institution. Through its main campus in Storrs, Conn., and its health center with both a medical and dental school, headquartered in Farmington, UCONN conducts extensive research in the fields of both basic and clinical human medicine, veterinary sciences, biotechnology, engineering, and a wide array of applied sciences. In 1997, UCONN received approximately $51 million from the federal government for research and more than $7 million from industry. BIO-INVESTIGATIONS LTD. holds the worldwide exclusive license in the field to this technology direct from the University of Connecticut. A venture capital firm heavily focused in the fields of human, veterinary, and agricultural health care, BIO-INVESTIGATIONS LTD. maintains relationships with universities and corporations worldwide. The firm often takes positions in innovative technologies in the form of exclusive options or worldwide licenses. DEKALB Genetics Corporation recently became part of the Monsanto Global Seed Group. The global seed business is central to Monsanto's future agricultural business strategy. "We are building a preeminent seed business capable of delivering elite germplasm coupled with cutting-edge technology to help growers improve their productivity and to meet ever-growing world food demands," said Bruce Bickner, co-president for the Monsanto Global Seed Group. DEKALB was the first company to genetically transform corn and emerged as a leader in the field of agricultural biotechnology. As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. The company's more than 30,000 employees worldwide make and market high-value agricultural products, pharmaceuticals and food ingredients. SOURCE DEKALB Genetics Corporation

To: Anthony Wong who wrote (918)	1/19/1999 12:11:00 PM
From: Dan Spillane	Read Replies (1) \| Respond to of 2539

They should fix the title of that article, it is incorrect. No clinical study shows what the title suggests. Looks like things happened pretty much as I expected (see my postings here and on Yahoo this past weekend). Notice, they emphasize the theoretical study doesn't translate into clinical results, just as I did. I am surprised to learn they already presented this to the FDA -- obviously this theoretical risk isn't enough to worry about. The article is titled: "New painkiller increases cardiac risk, study shows"